288148-34-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole-4-sulfonylchloride,1-methyl-(9CI) is used as a reagent for the preparation of benzoindazoles, which are glucocorticoid receptor modulators. These benzoindazoles have potential applications in the treatment of various inflammatory and immune-mediated disorders, as they can modulate the activity of the glucocorticoid receptor, a key regulator of inflammation and immune response.
In the synthesis of benzoindazoles, 1H-Pyrazole-4-sulfonylchloride,1-methyl-(9CI) serves as a key intermediate, providing a sulfonyl chloride group that can be further reacted with other organic compounds to form the desired benzoindazole structure. This reagent plays a crucial role in the development of new therapeutic agents with improved efficacy and safety profiles for the treatment of various diseases.

InChI:InChI=1/C3H3ClN2O2S/c4-9(7,8)3-1-5-6-2-3/h1-2H,(H,5,6)

Upstream product

• 930-36-9 1-methyl-1H-pyrazole 
• 39806-90-1 4-iodo-1-methyl-1H-pyrazole 

Downstream Products

• 1380229-22-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)-1-methyl-1H-pyrazole-4-sulfonamide 
• 1421919-08-5 ethyl 4-benzyl-6-(2-(1-methyl-1H-pyrazole-4-sulfonamido)ethoxy)chroman-3-ylcarbamate 

Relevant academic research and scientific papers

SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula (I) and their use in the treatment of migraine: where A is C(H)= or N=; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R2 is hydrogen or methyl; and R3 and R4 are as defined herein.

Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists

4-({2-[Isobutyl(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy}methyl)benzoic acid (1) is a functional PGE2 antagonist selective for EP1 receptor subtype. Analogs of 1, in which the phenyl-sulfonyl moiety has been replaced with more hydrophil

STEROID SPARING AGENTS AND METHODS OF USING SAME

This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.

Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia

This invention provides compounds of Formula I having the structure: wherein R1, R2, R3, R4, R5, R6, R7, R8, W, X, Y, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.